Valuation: Immunic, Inc.

Market Cap 202M 177M 163M 152M 287M 19.18B 292M 1.96B 760M 9.41B 757M 741M 32.76B P/E 2026 *
-3.38x
P/E 2027 * -4.18x
Enterprise Value -99.57M -87.42M -80.46M -74.98M -141M -9.47B -144M -968M -375M -4.65B -374M -366M -16.17B EV / Sales 2026 *
-
EV / Sales 2027 * -18.6x
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 day-0.37%
1 week-2.92%
Current month-4.81%
1 month-0.07%
3 months+26.12%
6 months+150.94%
Current year+174.12%
1 week 14.5
Extreme 14.5
15.84
1 month 11.55
Extreme 11.55
15.84
Current year 5.37
Extreme 5.372
15.84
1 year 5.06
Extreme 5.062
15.84
3 years 5.06
Extreme 5.062
31.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 2026-05-31
Director of Finance/CFO 58 2020-04-16
President 49 2024-07-11
Director TitleAgeSince
Director/Board Member 57 2018-12-31
Director/Board Member 59 2019-03-31
Chairman 55 2018-12-31
Date Insider Type Main position Quantity % Market Cap.
06-28Free

Director

25,370 0.1862%
06-28Free

Chief Financial Officer

120,000 0.8810%
06-28Free

Director

25,370 0.1862%
Change 5-day change 1-year change 3-year change Capi.($)
-0.37%-2.92%+105.19%-37.21% 202M
+3.98%+5.55%+76.40%+136.18% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+3.61%+8.56%-9.75%-9.39% 23.75B
+2.35%+5.34%+12.02%+430.36% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+2.30%+4.11%+25.10%+189.70% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +2.65%+6.59%+58.98%+125.34% 23.61B
Weighted average by Cap. +2.10%+6.09%+57.53%+135.87%

Financials

2026 *2027 *
Net sales - 11.11M 9.76M 8.98M 8.37M 15.78M 1.06B 16.1M 108M 41.85M 519M 41.72M 40.82M 1.8B
Net income -131M -115M -106M -98.56M -186M -12.44B -190M -1.27B -493M -6.11B -491M -481M -21.26B -137M -120M -110M -103M -194M -12.99B -198M -1.33B -515M -6.38B -513M -502M -22.19B
Net Debt -301M -265M -243M -227M -428M -28.65B -437M -2.93B -1.13B -14.06B -1.13B -1.11B -48.94B -408M -358M -330M -307M -580M -38.82B -592M -3.97B -1.54B -19.05B -1.53B -1.5B -66.31B
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
95
Date Price Change Volume
26-07-02 US$14.50 -2.09% 40,955
26-07-01 US$14.81 -3.64% 100,956
26-06-30 US$15.37 -0.26% 136,420
26-06-29 US$15.41 +0.72% 358,157
26-06-26 US$15.30 +1.53% 235,496
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.81USD
Average target price
44.67USD
Spread / Average Target
+201.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMUX Stock